As the next step, we examined whether the inhibition of the ERK-MAPK cascade seen in ECD patients treated with the MEK inhibitor (cobimetinib) has an effect on the levels of miR-15a-5p and CXCL10. This evidence concerns the gene CXCL10 and familial atrioventricular septal defect.